Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Trial number:
Trial phase:
Study type:
Chemotherapy, Targeted therapy
Overall status:

Study start date

September, 2020

Scientific title

A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)


The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

For patients with CLL:

• Confirmed diagnosis of chronic lymphocytic leukemia (CLL)

For patients with NHL:

Histologically confirmed diagnosis of B- or T-cell non-Hodgkins lymphoma (NHL).Must have a site of disease amenable to biopsy, and be suitable and willing to undergo study required biopsies at screening and during therapy.

Study design

Primary purpose: Treatment, Allocation: N/A, Intervention model: Single Group Assignment, Masking: None (Open Label),


Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia

Other study ID numbers


Choose trial site (12)